Chronic Cough

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Clinical judgment, based on the individual patient's presentation and comorbidities, is paramount. Drug dosages and recommendations may change; always consult current prescribing information and guidelines.

Overview

• Definition: Chronic cough is defined as a cough lasting for 8 weeks or longer in adults and 4 weeks or longer in children. It is a common and often challenging clinical problem that significantly impacts quality of life.
• Epidemiology: Chronic cough affects approximately 10-20% of the adult population, with higher prevalence in women, older individuals, and smokers. It is one of the most common reasons for physician visits. The three most common causes, often referred to as the "Big Three," account for over 90% of cases in non-smoking, non-ACE inhibitor-taking adults: Upper Airway Cough Syndrome (UACS), asthma (including cough-variant asthma, CVA), and gastroesophageal reflux disease (GERD).
• Classification:
  • Specific Chronic Cough: Cough with an identifiable underlying cause that can be treated (e.g., UACS, asthma, GERD, ACE inhibitor-induced cough, chronic bronchitis in smokers, non-asthmatic eosinophilic bronchitis).
  • Non-specific Chronic Cough: Cough for which initial standard investigations and empiric treatments fail to identify a specific cause. This category often leads to a diagnosis of "unexplained chronic cough" or "refractory chronic cough" (RCC) if it persists despite appropriate treatment of identified causes.

Pathophysiology

• Mechanism: The cough reflex is a complex neurophysiological event involving sensory afferent nerves (primarily vagal nerve C-fibers, A-delta fibers) originating from the airways, esophagus, and diaphragm, which transmit signals to the cough center in the brainstem. The cough center integrates these signals and initiates an efferent response via vagal, phrenic, and spinal motor nerves, leading to glottic closure, forced expiratory muscle contraction, and then glottic opening, resulting in a forceful expulsion of air. Chronic inflammation, irritation, hypersensitivity (due to neuronal plasticity or increased receptor expression), or mechanical stimulation of these pathways can lead to persistent coughing. The concept of "cough hypersensitivity syndrome" (CHS) is increasingly recognized as a unifying mechanism for many unexplained chronic cough cases, characterized by an exaggerated cough response to various stimuli.
• Risk Factors:
  • Smoking: Leading cause of chronic bronchitis and related cough.
  • Environmental Irritants: Exposure to allergens, pollutants, occupational irritants (e.g., dust, chemicals, fumes).
  • Medications: Angiotensin-converting enzyme (ACE) inhibitors (occurs in 5-20% of patients), beta-blockers (less common).
  • Underlying Medical Conditions: UACS (post-nasal drip), asthma, GERD, chronic obstructive pulmonary disease (COPD), bronchiectasis, interstitial lung disease, laryngeal dysfunction, chronic sinusitis.
  • Female Gender: Women are more prone to chronic cough, possibly due to hormonal influences on cough reflex sensitivity.
  • Obesity: May exacerbate GERD or contribute to airway hyperresponsiveness.
• Protective Factors:
  • Smoking Cessation: Most effective measure for smokers.
  • Avoidance of Irritants: Reducing exposure to allergens, pollutants, and occupational hazards.
  • Vaccinations: Influenza and pneumococcal vaccines may reduce the incidence of respiratory infections that can trigger or exacerbate chronic cough.
  • Control of Underlying Conditions: Effective management of asthma, GERD, and rhinosinusitis.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Cough lasting > 8 weeks (adults) or > 4 weeks (children).
  • Character: Can be dry, hacking, productive (with sputum), or barking.
  • Timing: Daytime predominance is common; nocturnal cough suggests asthma, GERD, or post-nasal drip.
  • Associated Symptoms:
    • UACS (Post-Nasal Drip Syndrome): Sensation of fluid dripping down the back of the throat, frequent throat clearing, nasal congestion, rhinorrhea, sneezing, hoarseness.
    • Asthma/Cough-Variant Asthma (CVA): Dyspnea, wheezing (often absent in CVA), chest tightness, cough triggered by exercise, cold air, or allergens. Nocturnal cough is common.
    • GERD: Heartburn, regurgitation, dysphagia, globus sensation, sour taste, hoarseness, dyspepsia. May be "silent" with no typical gastrointestinal symptoms.
    • Bronchiectasis: Chronic productive cough with purulent sputum, recurrent respiratory infections, hemoptysis.
    • Chronic Bronchitis (Smokers): Daily productive cough for at least 3 months of the year for 2 consecutive years.
    • Non-asthmatic Eosinophilic Bronchitis (NAEB): Dry or minimally productive cough, often without wheezing or dyspnea, and normal spirometry. Diagnosed by sputum eosinophilia.
• Early Signs: In some cases, the cough may start as acute, then persist and develop into chronic. Early indicators of potential chronicity include persistent post-viral cough, or cough associated with subtle signs of UACS, asthma, or GERD.
• Advanced Signs: For chronic cough, "advanced" typically refers to the duration and its impact. Persistent cough that has significantly affected quality of life, caused complications (e.g., syncope, rib fracture), or remained undiagnosed despite extensive workup.
• Atypical Presentations:
  • Silent GERD: Cough due to GERD without classic heartburn or regurgitation.
  • Cough Syncope: Fainting spells induced by severe paroxysms of coughing.
  • Habit Cough (Psychogenic Cough): Barking or honking cough that is typically absent during sleep, not associated with other symptoms, and often resolves with behavioral interventions. More common in children and adolescents.
  • Laryngeal Hypersensitivity: Cough triggered by minimal laryngeal stimuli, sometimes accompanied by throat clearing, dysphonia, or globus sensation.

Physical Examination

Often normal, especially in cough-variant asthma or silent GERD. Focused examination should include: - Inspection: * Nasal cavity: Mucosal edema, discharge, polyps (suggests rhinitis/sinusitis). * Pharynx/Oropharynx: "Cobblestoning" of posterior pharynx (lymphoid hyperplasia consistent with PND), post-nasal drip visualized. * Neck: Thyroid enlargement, lymphadenopathy. * Chest wall: Evidence of rib fracture (pain on palpation), tenderness over sternum/ribs (costochondritis from cough). * Signs of respiratory distress, clubbing, cyanosis (suggests severe underlying lung disease). - Palpation: * Sinuses: Tenderness over maxillary/frontal sinuses (sinusitis). * Neck: Lymph nodes. * Trachea: Deviation (mass effect). * Chest: Tenderness (rib fracture, costochondritis). - Auscultation: * Lungs: Wheezing (asthma), crackles (bronchiectasis, ILD, heart failure), rhonchi (bronchitis). Clear lung sounds are common in UACS, CVA, GERD, and unexplained cough. * Heart: Murmurs, gallops (cardiac causes of cough). - Special Tests: * Laryngoscopy (indirect or fiberoptic): For vocal cord dysfunction, laryngeal irritation, or structural abnormalities (e.g., polyps, tumors, chronic laryngitis). May be performed by an ENT specialist.

Diagnostic Approach

The diagnostic approach for chronic cough is largely driven by a thorough history and physical examination, followed by a systematic investigation for the common causes before considering less common etiologies or a diagnosis of unexplained chronic cough.

History Taking

• Key Questions:
  • Duration and Onset: When did it start? Was it acute or insidious?
  • Character of cough: Dry, productive (color, consistency, volume of sputum), hacking, barking, paroxysmal.
  • Timing: Worse at night, in the morning, after meals, with exercise, during specific seasons, in certain environments.
  • Triggers: Cold air, exercise, allergens, irritants (perfume, smoke), speaking, eating.
  • Associated Symptoms: Nasal congestion, rhinorrhea, throat clearing, hoarseness, dysphagia, heartburn, regurgitation, chest pain, dyspnea, wheezing, weight loss, fever, hemoptysis.
  • Medication History: Especially ACE inhibitors, beta-blockers, inhaled medications.
  • Smoking History: Current or past, duration, pack-years.
  • Environmental/Occupational Exposures: Dust, chemicals, allergens.
  • Past Medical History: Asthma, allergies, GERD, chronic sinusitis, recurrent pneumonia, autoimmune diseases.
  • Impact on Quality of Life: Sleep disturbance, social embarrassment, incontinence, syncope, pain.
• Red Flags: These signs and symptoms warrant urgent and thorough investigation to rule out serious underlying pathology:
  • Hemoptysis: Coughing up blood.
  • Dyspnea: Especially new or worsening.
  • Weight loss
  • Fever
  • New onset cough in a smoker or former smoker
  • Hoarseness (especially persistent)
  • Recurrent pneumonia
  • Abnormal chest X-ray (prior or current)
  • Dysphagia (difficulty swallowing)
  • Neurological signs (e.g., headache, focal weakness)
  • Signs of systemic illness (e.g., night sweats, malaise)

Laboratory Tests

Laboratory tests are generally not first-line for chronic cough unless specific conditions are suspected. - First-Line (If indicated by history/exam): * Complete Blood Count (CBC): May show eosinophilia if parasitic infection or severe allergic disease/eosinophilic bronchitis is suspected, though not diagnostic. * Inflammatory markers (ESR, CRP): Non-specific, but may be elevated in systemic inflammatory conditions. * Sputum analysis (culture and cytology): If productive cough with purulent sputum, to identify bacterial pathogens or atypical cells. Rarely helpful for dry cough. * Allergy testing (skin prick or specific IgE): If environmental allergies or asthma are suspected triggers. - Confirmatory: * Induced Sputum Cell Count: For suspected non-asthmatic eosinophilic bronchitis (NAEB). Sputum eosinophil count >3% supports NAEB. - Monitoring: Not typically used for monitoring chronic cough itself, but for monitoring the underlying condition (e.g., blood tests for systemic inflammation, asthma control tests).

Imaging

• Recommended (First-Line):
  • Chest X-ray (CXR): Crucial initial step for all adult patients with chronic cough and no obvious cause (e.g., clear history of ACE-inhibitor use). It screens for underlying lung pathology (e.g., masses, infiltrates, bronchiectasis, interstitial lung disease, cardiomegaly). A normal CXR is common in the "Big Three" causes.
• Advanced (If CXR is abnormal or cough is unexplained/refractory):
  • High-Resolution Computed Tomography (HRCT) of the Chest: Indicated if CXR is abnormal or if there is a strong suspicion of structural lung disease (e.g., bronchiectasis, interstitial lung disease, lung mass) despite a normal CXR. Provides detailed imaging of lung parenchyma.
  • CT Scan of Paranasal Sinuses: If chronic rhinosinusitis is strongly suspected but nasal exam is non-diagnostic.
  • Barium Swallow or Esophagram: Rarely used, but may be considered for suspected aspiration or esophageal motility disorders contributing to cough.

Other Diagnostic Tests

• Pulmonary Function Tests (PFTs) with Bronchodilator Response:
  • Spirometry: Screens for airflow obstruction (COPD, asthma). A normal spirometry does not rule out asthma (especially CVA).
  • Bronchodilator responsiveness: Significant improvement in FEV1 (typically >12% and >200mL) post-bronchodilator is suggestive of asthma.
• Bronchial Challenge Test (Methacholine, Mannitol, Histamine): If asthma/CVA is suspected but spirometry is normal. A positive test indicates airway hyperresponsiveness. A negative test makes asthma unlikely.
• 24-hour Esophageal pH Monitoring with Impedance: "Gold standard" for detecting acid and non-acid reflux, especially for silent GERD. Often considered for cough refractory to empiric PPI trials.
• Upper Endoscopy: May be considered if GERD is suspected and alarm symptoms are present, or if empiric PPI trial fails.
• ENT Consultation/Fiberoptic Laryngoscopy: For suspected laryngeal causes (e.g., vocal cord dysfunction, chronic laryngitis, structural lesions) or UACS evaluation.
• Bronchoscopy: Rarely indicated unless there are suspicious findings on imaging (e.g., mass, localized infiltrate, foreign body) or for persistent unexplained hemoptysis.
• Specific Biomarkers: Fractional exhaled nitric oxide (FeNO) can be elevated in eosinophilic airway inflammation (asthma, NAEB). Values >25 ppb (adults) or >20 ppb (children) can support the diagnosis of eosinophilic airway disease.

Management

Management of chronic cough is primarily etiology-driven. A systematic approach focusing on the most common causes first is recommended.

Acute Management

Acute management for chronic cough refers more to the initial systematic diagnostic workup rather than emergent interventions, unless a red flag is present. - Immediate: Address any red flags first (e.g., hemoptysis requires urgent imaging/bronchoscopy). - Stabilization: If an acute exacerbation of an underlying chronic condition (e.g., asthma flare, pneumonia) is identified, treat the acute event. - Emergency: Not typically relevant for chronic cough unless complications like severe respiratory distress, syncope with injury, or pneumothorax occur.

Chronic Management

The cornerstone of chronic cough management involves treating the underlying cause(s). If multiple causes are suspected, they should be addressed simultaneously or sequentially.

Pharmacological

1. Upper Airway Cough Syndrome (UACS) / Post-Nasal Drip Syndrome (PNDS):
   • First-line: Treat underlying rhinitis/sinusitis.
     • First-generation antihistamine-decongestant combination: e.g., brompheniramine/pseudoephedrine 4 mg/60 mg orally every 4-6 hours, or triprolidine/pseudoephedrine. Often effective due to anticholinergic and drying effects.
     • Intranasal corticosteroids: e.g., fluticasone propionate 50 mcg/nostril once or twice daily, mometasone furoate 50 mcg/nostril once daily. Effective for allergic or non-allergic rhinitis. Takes 2-4 weeks for full effect.
     • Nasal saline irrigation: Daily large-volume irrigation (e.g., Neti-Pot) helps clear mucus and irritants.
   • Duration: Treat for 2-4 weeks; if cough improves, continue for 2-3 months.
2. Asthma / Cough-Variant Asthma (CVA) / Non-asthmatic Eosinophilic Bronchitis (NAEB):
   • First-line:
     • Inhaled Corticosteroids (ICS): e.g., fluticasone 88-220 mcg BID, budesonide 90-360 mcg BID. Requires consistent use for several weeks for full effect.
     • Short-acting Beta-agonists (SABA): e.g., albuterol MDI 2 puffs as needed for cough/bronchospasm relief.
   • Add-on (if ICS alone insufficient):
     • Long-acting Beta-agonists (LABA): Always in combination with ICS (e.g., fluticasone/salmeterol, budesonide/formoterol).
     • Leukotriene Receptor Antagonists (LTRAs): e.g., montelukast 10 mg daily. Can be useful, especially if there's an allergic component.
   • Duration: Treatment for asthma/NAEB is usually long-term. Cough improvement often seen within 1-2 weeks.
3. Gastroesophageal Reflux Disease (GERD)-related Cough:
   • First-line (Empiric trial):
     • Proton Pump Inhibitors (PPIs): e.g., omeprazole 20-40 mg BID, lansoprazole 30 mg BID, esomeprazole 20-40 mg BID. Administer 30-60 minutes before breakfast and dinner.
   • Duration: A trial of high-dose PPI for 8-12 weeks is recommended, as cough improvement can be delayed. Up to 6 months may be needed for full resolution.
   • Lifestyle modifications (see Non-pharmacological).
4. ACE Inhibitor-induced Cough:
   • Management: Discontinue the ACE inhibitor. Cough typically resolves within 1-4 weeks (may take up to 3 months). Switch to an Angiotensin Receptor Blocker (ARB) if blood pressure control is still needed.
5. Refractory Chronic Cough (RCC) / Unexplained Chronic Cough (UCC): If no specific cause is found after a thorough evaluation and empiric trials, or if cough persists despite optimal treatment of identified causes.
   • Neuromodulators: Target cough hypersensitivity.
     • Gabapentin: Start low (e.g., 300 mg once daily at night) and titrate slowly to effect and tolerability (e.g., 300 mg TID or 600 mg BID, max 1800-2400 mg/day). Side effects: dizziness, somnolence, fatigue.
     • Pregabalin: Start low (e.g., 75 mg BID) and titrate slowly (max 300 mg BID). Side effects: dizziness, somnolence, peripheral edema.
     • Other options (less evidence/more side effects): Low-dose tricyclic antidepressants (e.g., amitriptyline 10-25 mg at night), speech therapy.
   • Potassium-competitive acid blockers (P-CABs): Gefapixant (P2X3 receptor antagonist) is a newer option approved for RCC. Dose: 45 mg BID. Side effects include dysgeusia (taste disturbance, common), nausea. High cost, limited long-term data.
   • Non-specific Antitussives: Generally less effective for chronic cough and not recommended as first-line for RCC.
     • Dextromethorphan: 10-30 mg every 4-8 hours.
     • Guaifenesin: 200-420 mg every 4 hours. Expectorant, less evidence for cough suppression.
     • Codeine/Hydrocodone: Opioid antitussives. Risk of dependence, sedation, constipation. Use is generally discouraged for chronic cough due to side effects and limited long-term efficacy.
     • Benzonatate: 100-200 mg TID. Local anesthetic. Evidence for efficacy is weak.
     • Menthol lozenges: Provide temporary symptomatic relief.

Non-pharmacological

• Lifestyle Modifications (for GERD): Elevate head of bed, avoid trigger foods (fatty foods, chocolate, caffeine, alcohol, spicy foods), eat smaller meals, avoid eating close to bedtime (2-3 hours before).
• Cough Suppression Therapy / Speech Pathology: A specialized program often involves breathing exercises, laryngeal desensitization techniques, cough control strategies, and education. Increasingly recognized as an effective treatment for RCC.
• Humidification: May help some patients, especially in dry environments.
• Avoidance of Irritants: Eliminating exposure to tobacco smoke (including secondhand), strong perfumes, chemical fumes, and environmental allergens.

Monitoring

• Symptom Resolution: Regular follow-up to assess improvement in cough frequency, severity, and impact on quality of life.
• Side Effects: Monitor for adverse effects of medications.
• Re-evaluation: If cough does not improve after appropriate trials of therapy, re-evaluate the diagnosis and consider less common causes or referral to a specialist.

Treatment Algorithms

A step-wise, diagnostic-therapeutic approach is generally recommended:

1. Initial Assessment:
   • Thorough History & Physical Exam: Identify red flags, medication use (ACEi), smoking status.
   • Chest X-ray: Rule out serious lung pathology.
   • Smoking Cessation: Counsel all smokers.
   • Discontinue ACE inhibitors: If patient is on one.
2. Empiric Trials (if no red flags and CXR is normal): Based on common etiologies.
   • First-Line:
     • Treat UACS/PNDS: Empiric trial of a first-generation antihistamine/decongestant combination + intranasal corticosteroids for 2-4 weeks.
     • If symptoms suggest asthma/CVA: Perform spirometry. If abnormal, treat for asthma (ICS +/- LABA, LTRA). If normal, consider bronchial challenge test.
     • If symptoms suggest GERD (even silent): Empiric trial of high-dose PPI BID for 8-12 weeks.
   • Second-Line (if cough persists after 1st line trials or specific diagnosis made):
     • If UACS response incomplete, consider CT sinuses or ENT referral.
     • If asthma suspected: Proceed with bronchial challenge test if spirometry normal, and treat if positive. Consider FeNO.
     • If GERD suspected and PPIs fail: Consider 24-hour pH impedance monitoring or specialized GI evaluation.
     • Consider NAEB (induced sputum for eosinophils) if asthma treatments don't work but eosinophilic inflammation is suspected.
3. Refractory Cases (Unexplained Chronic Cough - UCC / Refractory Chronic Cough - RCC):
   • If cough persists despite addressing the "Big Three" and other identifiable causes, and all investigations are negative, consider UCC/RCC.
   • Multidisciplinary approach: Referral to specialists (Pulmonologist, ENT, Gastroenterologist, Speech Pathologist, Allergy/Immunology).
   • Neuromodulators: Trial of gabapentin or pregabalin.
   • Cough Suppression Therapy: Referral to speech pathologist trained in cough control.
   • Gefapixant: Consider for severe RCC in eligible patients, weighing benefits against side effects and cost.
   • Psychological Support: For associated anxiety, depression, or habit cough.

Complications

• Common:
  • Fatigue and Sleep Disturbance: Due to constant coughing.
  • Voice Changes/Hoarseness: From vocal cord irritation.
  • Musculoskeletal Pain: Chest wall pain, abdominal muscle strain.
  • Urinary Incontinence: Especially in women, particularly during paroxysms of coughing.
  • Social Embarrassment and Isolation: Affects quality of life, leading to anxiety and depression.
  • Cough Syncope: Fainting due to reduced cerebral blood flow during severe cough.
• Serious:
  • Rib Fractures: Especially in osteoporotic individuals.
  • Pneumothorax: Rare, but can occur with forceful coughing.
  • Subconjunctival Hemorrhage: From increased intrathoracic pressure.
  • Worsening of underlying medical conditions: e.g., heart failure, hypertension.
• Long-term:
  • Anxiety and Depression: Chronic nature of cough can lead to psychological distress.
  • Reduced Quality of Life: Impaired social, physical, and emotional well-being.
  • Chronic Laryngitis/Vocal Cord Dysfunction: Prolonged irritation.

Prognosis

• Factors:
  • Identifiable Cause: Prognosis is generally good if a specific underlying cause can be identified and adequately treated.
  • Duration of Cough: Longer duration before diagnosis and treatment may correlate with slower resolution, especially for refractory cases.
  • Comorbidities: Presence of multiple contributing factors or other chronic diseases can complicate management.
  • Patient Compliance: Adherence to treatment regimens.
  • Cough Hypersensitivity: If significant, can make resolution challenging.
• Survival: Chronic cough itself is rarely life-threatening, but it can be a symptom of serious underlying conditions (e.g., lung cancer, heart failure, severe pulmonary fibrosis). Once serious conditions are ruled out, the impact is primarily on morbidity and quality of life, not direct mortality.
• Quality of Life: Significantly impaired in patients with chronic cough. Successful treatment improves physical, social, and psychological well-being. Refractory cough can lead to chronic distress and reduced daily functioning.

Prevention

• Primary:
  • Smoking Cessation: The most important primary prevention measure for chronic bronchitis and related cough.
  • Avoidance of Environmental Irritants and Allergens: Minimizing exposure to triggers.
  • Vaccinations: Routine influenza and pneumococcal vaccinations can prevent respiratory infections that might initiate or exacerbate chronic cough.
  • Prompt Treatment of Acute Respiratory Infections: To prevent progression to chronic cough.
• Secondary:
  • Early Diagnosis and Treatment: Promptly identifying and treating conditions like asthma, GERD, and rhinosinusitis before cough becomes chronic or deeply established.
  • Medication Review: Regular review of patient medications, especially ACE inhibitors.
• Tertiary:
  • Optimizing Management of Underlying Conditions: Strict control of asthma, GERD, and rhinosinusitis to prevent exacerbations and persistence of cough.
  • Cough Control Strategies: Teaching patients techniques to suppress or manage coughing spells to prevent complications (e.g., incontinence, syncope).
  • Supportive Care: Addressing psychological impact and complications to improve quality of life.

Special Populations

• Pediatric:
  • Definition: Chronic cough is usually defined as >4 weeks in children.
  • Common Causes: More commonly post-infectious cough, asthma (especially CVA), inhaled foreign body, protracted bacterial bronchitis (PBB), and habit cough. GERD is less common as a primary cause than in adults.
  • Diagnosis: Less reliance on empiric trials; often requires more specific testing earlier. Bronchoscopy may be considered earlier for suspected foreign body or PBB.
  • Management: Focus on treating underlying cause. Antibiotics for PBB (e.g., amoxicillin-clavulanate for 2-4 weeks). Habit cough often responds to reassurance and behavioral therapy.
• Geriatric:
  • Increased Prevalence: Due to higher rates of chronic diseases.
  • Polypharmacy: Increased risk of ACE inhibitor-induced cough and drug-drug interactions.
  • Atypical Presentations: Less prominent symptoms of asthma or GERD.
  • Increased Risk of Complications: Rib fractures, urinary incontinence, cough syncope, and aspiration pneumonia are more common.
  • Assessment: Thorough medication review is crucial.
• Pregnancy:
  • Diagnostic Challenges: Limited use of imaging (CXR only if highly indicated, with shielding).
  • Management Challenges: Restricted medication options. First-line treatments generally include lifestyle modifications for GERD, saline nasal sprays for UACS, and inhaled corticosteroids for asthma (lowest effective dose, generally safe). Avoid decongestants and first-generation antihistamines in the first trimester. Opioids are generally avoided.
  • GERD often worsens during pregnancy.
• Comorbidities:
  • COPD: Cough is often chronic and productive. Management focuses on COPD optimization. Chronic cough may signify a COPD exacerbation or bronchiectasis.
  • Interstitial Lung Disease (ILD): Cough is often dry and persistent. Management focuses on ILD treatment, though specific antitussives may be needed.
  • Heart Failure: Cough typically accompanies dyspnea on exertion, orthopnea, and peripheral edema. Management is directed at optimizing cardiac function.
  • Immunocompromised Patients: Higher risk of opportunistic infections as a cause of cough. Requires specific diagnostic workup and treatment.

Clinical Pearls

• Diagnostic:
  • Always exclude red flags first with a thorough history, physical exam, and Chest X-ray.
  • ACE inhibitors are a common and easily reversible cause; always review medication list.
  • The "Big Three" (UACS, asthma, GERD) account for >90% of cases in non-smokers not on ACEi. Focus empiric treatment on these.
  • Silent GERD is common: Do not rule out GERD as a cause based solely on absence of typical GI symptoms.
  • Cough-Variant Asthma lacks classic wheezing; it's a common cause of chronic cough. Consider bronchial challenge if suspicion is high and spirometry is normal.
  • Empiric trials should be adequate duration: e.g., PPIs for 8-12 weeks, intranasal steroids for 2-4 weeks. Patience is key.
  • If cough persists after initial targeted therapy, re-evaluate: Revisit history, consider less common causes, or proceed to specialized investigations.
• Treatment:
  • Treat the underlying cause: Symptomatic relief alone is rarely sufficient for chronic cough.
  • Multifactorial approach: Many patients have more than one contributing factor. Address all identified causes.
  • Cough hypersensitivity: Even after successful treatment of underlying causes, hypersensitivity may persist. Neuromodulators or speech therapy may be beneficial for RCC.
  • Patient education: Explain the diagnostic process and treatment plan. Manage expectations about resolution time.
• Pitfalls:
  • Over-reliance on non-specific antitussives: These provide only temporary relief and do not address the underlying cause.
  • Inadequate duration of empiric trials: Stopping treatment too early before full effect is achieved.
  • Failure to consider less common causes: After ruling out common causes, broaden the differential.
  • Missing "silent" causes: e.g., silent GERD, cough-variant asthma.
  • Ignoring the psychological impact: Chronic cough can severely impact mental health; address anxiety and depression.
  • Ordering too many tests too early: A systematic, algorithmic approach saves time and resources.

Recent Updates

• Guidelines: The American College of Chest Physicians (CHEST) and European Respiratory Society (ERS) guidelines on chronic cough are regularly updated. The 2020 CHEST guidelines emphasize a shift towards diagnosing and treating the underlying disease rather than categorizing cough as "specific" or "non-specific" until a cause is found.
• Evidence: Increased understanding of the "Cough Hypersensitivity Syndrome" (CHS) as a common pathophysiological mechanism for unexplained and refractory chronic cough. This has led to the development of neuromodulating drugs and greater emphasis on non-pharmacological cough suppression therapy.
• Pharmacological Advancements: Gefapixant, a P2X3 receptor antagonist, was approved in some regions for refractory chronic cough, representing a new class of antitussives targeting afferent nerve sensitization. Its role in routine practice is still evolving given side effects (dysgeusia) and cost.
• Role of Speech Pathology: Growing evidence supports the effectiveness of cough suppression therapy delivered by speech-language pathologists for RCC, often more effective and with fewer side effects than pharmacotherapy alone.
• Precision Medicine: Future directions aim for more personalized treatment based on cough phenotype and endotype, including inflammatory markers or genetic predispositions.

Key References

• Guidelines:
  • Irwin, R. S., et al. (2020). CHEST Guideline and Expert Panel Report: Management of Cough in the Adult. Chest, 158(2), 527-542. (Comprehensive, algorithm-driven, updated recommendations).
  • Morice, A. H., et al. (2020). ERS guidelines on the assessment and management of chronic cough. European Respiratory Journal, 55(1), 1901136. (European perspective, also very comprehensive).
  • Mazzone, S. B., & McGarvey, L. P. (2020). Refractory chronic cough: a clinical and research perspective. European Respiratory Journal, 55(1), 1901456. (Focus on RCC and mechanisms).
• Studies/Reviews:
  • Dicpinigaitis, P. V. (2023). Chronic cough. New England Journal of Medicine, 388(17), 1591-1600. (Excellent recent review).
  • Smith, J. A., et al. (2020). Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory chronic cough: results from two phase 3 randomised, controlled trials. The Lancet Respiratory Medicine, 8(7), 653-661. (Key study on a new treatment).
  • Vertigan, A. E., et al. (2013). Speech pathology management of chronic cough. Journal of Clinical Outcomes Management, 20(3), 143-150. (Illustrates the role of non-pharmacological therapy).
  • Kahrilas, P. J., & Spechler, S. J. (2021). Gastroesophageal reflux disease and chronic cough. Current Opinion in Gastroenterology, 37(4), 385-391. (Updated perspective on GERD-cough link).